2007•Zhongguo yaofangRequires access

Three Therapeutic Schemes for Chronic Hepatitis B:Cost-Effectiveness Analysis

Chen Yan

Abstract

OBJECTIVE:To compare the cost-effectiveness of 3 therapeutic schemes in the treatment of the chronic Hepatitis B.METHODS:The medication data for the treatment of the chronic Hepatitis B were investigated,and the therapeutic schemes were divided into 3 groups:Interferon plus sophorcarpidine(Group A),Interferon plus thymopeptide(Group B) and lamivudine plus ophorcarpidine(Group C).The medication duration was 90 days for all the 3 groups.The cost-effectiveness analysis was performed using the theory of pharmacoeconomics.RESULTS:The 3 groups showed no significant differences in clinical efficacy,but significant differences in costs were noted.CONCLUSION:Group B is preferable for chronic Hepatitis B in terms of cost-effectiveness.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Lamivudine, Pharmacoeconomics, Medicine, Chronic hepatitis, Internal medicine, Hepatitis B, Group B, Interferon